Gilead Sciences Price Target Raised to $84.00 at Argus (GILD)
Equities research analysts at Argus raised their target price on shares of Gilead Sciences (NASDAQ:GILD) from $70.00 to $84.00 in a research note issued to investors on Friday, American Banking News reports. The firm currently has a “buy” rating on the stock. Argus’ price target points to a potential upside of 18.02% from the company’s current price. The analysts noted that the move was a valuation call.
A number of other analysts have also recently weighed in on GILD. Analysts at Barclays raised their price target on shares of Gilead Sciences from $68.00 to $74.00 in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note to investors on Wednesday. They now have a $73.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences to $85.00 in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. Six investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $71.70.
Gilead Sciences (NASDAQ:GILD) opened at 70.50 on Friday. Gilead Sciences has a 52 week low of $30.955 and a 52 week high of $73.20. The stock has a 50-day moving average of $64.74 and a 200-day moving average of $58.03. The company has a market cap of $107.9 billion and a P/E ratio of 39.83. Gilead Sciences also was the target of some unusual options trading on Wednesday. Stock traders acquired 24,047 call options on the stock. This represents an increase of approximately 109% compared to the average volume of 11,512 call options.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 14.7% on a year-over-year basis. Analysts expect that Gilead Sciences will post $1.99 EPS for the current fiscal year.
In other Gilead Sciences news, EVP Kevin Young unloaded 75,000 shares of the stock on the open market in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $68.56, for a total transaction of $5,142,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.